Vimta Labs Share Price Analysis: Targets 2026 to 2030 and Fundamentals

Vimta Labs share price today

The Vimta Labs share price invites an unusual kind of question, because the business behind it is easy to describe and hard to value. Vimta runs laboratories. Somebody has to test a drug batch, a food consignment, a medical device, an effluent stream or an electronic component before it can legally be sold, and Vimta is paid to run that test and sign the report. Demand is created by regulation rather than by fashion. The valuation question is what a stream of regulated testing fees is worth once it is already priced at more than thirty-five times trailing earnings.

At the 10 September 2026 close, Yahoo Finance showed a price of ₹629.05, market capitalisation of about ₹2,810 crore and trailing EPS of ₹17.84. That is roughly 35.26 times trailing earnings and 6.15 times a book value of ₹102.28 per share. The quote above keeps moving after publication; every ratio and scenario input below stays fixed to that cut-off.

The last twelve months contain the tension in a single pair of numbers. Over five years, figures dated 5 August 2026 put sales growth at a compound 14.27% and profit growth at 29.96% a year. The most recent year-on-year readings from Yahoo are 11.8% revenue growth and 10.7% earnings growth. The share has behaved accordingly: against a 52-week range of ₹380.70 to ₹825.05, the price sits about 23.76% below the high and roughly 65% above the low. A stock rated for thirty per cent compounding is currently delivering about ten.

One disclosure before anything else. No Screener financial statement tables were captured for this company in this research pass. The multi-year figures below come from Yahoo Finance’s annual rows and from the Screener-derived ratio set dated 5 August 2026. No recent quarterly income statement was captured, so this article contains no quarterly results section and no quarterly numbers have been estimated to fill the gap.

What Vimta Labs actually sells

Vimta Labs was founded in 1984 and is headquartered in Hyderabad. It describes itself as a contract research and testing organisation serving customers in India and internationally, and it employed 1,384 people at the date of the Yahoo company record. The revenue base is not one service but a portfolio of regulated testing and research work, which is why the company sits under the healthcare label while a large part of its order flow has nothing to do with medicine.

Service line	What the customer buys	Who pays for it	Economic characteristic
Preclinical and clinical research	Drug discovery, development and life-cycle support studies	Biopharmaceutical companies	Long study cycles, high accreditation barrier
Analytical services	Method development and batch analysis	Pharma and biologics manufacturers	Recurring, tied to production volume
Medical device testing	Preclinical research and device evaluation	Device manufacturers	Growing with domestic device manufacturing
Food and beverage testing	Food, water, alcoholic and non-alcoholic beverage analysis	Processors, exporters, retailers, regulators	High volume, compliance-driven, repeat
Environmental services	Impact assessments and post-project monitoring	Power, cement, oil and gas, mining, infrastructure	Project-linked, follows the capex cycle
EMI/EMC testing	Electromagnetic testing of electronic components	Electrical and electronics manufacturers	Capital-intensive chambers, few credible providers

The spread matters more than any single line. Pharmaceutical research spending is cyclical and can be deferred; food, water and environmental compliance testing is much harder to postpone because a consignment cannot ship or a plant cannot operate without the certificate. A laboratory group that carries both is less exposed to any one customer budget than a pure contract research organisation, and it is also structurally harder to run, because each vertical needs its own instruments, accreditations and inspectors.

The long-run record, and the gaps in it

Only a handful of annual rows were captured, and they are widely spaced. They are presented here as they stand, with the gaps left visible rather than filled.

Financial year ended March	Revenue	Net profit
FY11	₹96 Cr	Not captured
FY17	₹153 Cr	₹10 Cr
FY18	₹181 Cr	₹16 Cr
FY25	Not captured	₹67 Cr
Trailing twelve months (Yahoo, captured 10 Sep 2026)	₹421 Cr	About ₹80 Cr, implied

The implied trailing profit is arithmetic, not a reported line: EPS of ₹17.84 across 44,686,904 shares gives about ₹80 crore, and Yahoo’s trailing net margin of 18.91% on revenue of ₹421 crore points to the same figure. The trailing window closes at the last quarter Yahoo had on file rather than at the capture date, and that quarter is not named in the captured data, which is why the row is dated by capture rather than by period end. Read against FY25’s ₹67 crore, the direction is up. Read against the FY17 base of ₹10 crore, the long-run record is genuinely strong. The 29.96% five-year profit CAGR dated 5 August 2026 covers a later window whose starting year was not captured, so it cannot be tied to the FY17 figure.

The gap between FY18 and FY25 is not something to paper over. Anyone underwriting this company properly should pull the intervening annual reports from the company’s investor page and rebuild the series, particularly the years around the pandemic, when clinical research volumes and environmental fieldwork moved in opposite directions.

Margins, returns and a balance sheet with almost no debt

This is where the business quality shows up. The operating margin captured on 5 August 2026 was 34.66%, and Yahoo’s own numbers corroborate it: EBITDA of ₹147 crore on revenue of ₹421 crore is close to 35%. Yahoo separately reports a 22.7% operating margin, which is the same business after depreciation. The twelve-point gap is the honest signal here. Laboratories are capital-intensive. Instruments, animal facilities and EMI/EMC chambers depreciate hard, and a large slice of gross margin is consumed keeping the estate current.

Measure	Reading	Why it matters
Operating margin	34.66%	Pricing power from accreditation, before depreciation
EBITDA	₹147 Cr	Consistent with the margin above on ₹421 Cr of revenue
Operating margin after depreciation	22.7%	The real cost of keeping laboratory assets current
ROCE	25.23%	Capital is earning well above a plausible cost of capital
Five-year average ROCE	23.87%	The current return is not a one-year spike
ROE	18.87%	Post-tax return; no leverage is lifting it above ROCE
Total debt	₹3 Cr	Debt-to-equity of 0.729%
Total cash	₹66 Cr	Net cash of about ₹63 Cr
Promoter holding	65.68%	Pledged shares: nil
Dividend yield	0.32%	The case rests on reinvestment, not income

A five-year average ROCE of 23.87% against a current 25.23% is the most reassuring line in the table, because it says the return is a characteristic of the business rather than an artefact of one good year. ROCE is measured before tax and ROE after it, which accounts for most of the gap between them: 25.23% taxed at roughly a quarter lands almost exactly on 18.87%. What the ₹3 crore of debt against roughly ₹457 crore of net worth tells you is that no leverage is being used to flatter the equity return — borrowed money would normally push ROE above the post-tax return on capital employed, and here it does not. Promoters hold 65.68% with nothing pledged, which removes a common source of micro-cap accident.

Why an accredited laboratory can compound

The moat, if there is one, is not the equipment. It is permission. A testing report is only commercially useful if the regulator or the buyer accepts it, and acceptance comes from accreditations that take years to win and can be withdrawn after a bad inspection. Vimta’s own website lists recognition from bodies including USFDA, MHRA, TGA, ANVISA, WHO-GMP and OECD GLP internationally, and NABL, ISO/IEC 17025, NABCB, BIS and FSSAI in India. A competitor with the same instruments and no accreditation history is not a substitute.

Three demand drivers sit behind that. Indian pharmaceutical and biologics manufacturers are exporting into regulated markets that require documented analytical work. Food safety and water testing enforcement in India has been tightening for a decade. And environmental compliance monitoring is attached to an infrastructure and power capex cycle that has been running hard. None of these is a fashion; all of them are budget lines that survive a slowdown.

The counter-argument is equally simple. Testing is fragmented and competitive at the commodity end, global players and captive in-house laboratories both compete for the regulated end, and pricing on repeat food or water panels is far weaker than pricing on a bespoke clinical study. Mix, not volume, decides whether the 34.66% margin holds. The related work published on Anthem Biosciences and Divi’s Laboratories covers the same regulated-supply-chain demand from the manufacturing side of the trade.

What the Vimta Labs share price is discounting

At 35.26 times trailing earnings, the market is not paying for a laboratory that grows revenue at 11.8%. It is paying for the five-year record. The PEG of 1.19 makes that explicit: divide the P/E of 35.26 by that PEG and you recover a growth assumption near 30% a year, which is almost exactly the five-year profit CAGR of 29.96%. Substitute the most recent 10.7% earnings growth instead and the same P/E implies a PEG above three.

That is the whole argument in one line. The multiple is anchored to history and the recent trend is running well below it. This does not make the stock expensive by itself, because a single decelerating year in a project-driven laboratory business is not proof of a new run rate. It does mean the burden of proof has moved. If the P/E is to be defended, growth has to reaccelerate; if it does not, the earnings can keep rising while the multiple falls.

Market capitalisation was ₹2,875 crore on 5 August 2026 against ₹2,810 crore on 10 September, so the de-rating has already begun in a small way. Note also that the 52-week high in the earlier capture was ₹877.20 against ₹825.05 in the later one, which is simply the rolling window dropping an older peak, not a correction to the data.

Valuation at the research cut-off

Valuation measure	10 September 2026 reading	Interpretation
Completed-session price	₹629.05	Fixed research input, not a live quote
Market capitalisation	About ₹2,810 Cr	Micro-cap: liquidity and disclosure depth both matter
Trailing EPS	₹17.84	Yahoo Finance trailing basis
Recalculated P/E	About 35.26×	Price divided by trailing EPS
Book value per share	₹102.28	Implies price-to-book of 6.15×
EV/EBITDA	18.01	Slightly kinder than the P/E, helped by net cash
PEG	1.19	Computed against five-year, not current, growth
ROCE / ROE	25.23% / 18.87%	Genuinely good returns on capital employed
Dividend yield	0.32%	Nominal; earnings are retained

Six times book for a business earning 18.87% on equity is not absurd, but it leaves little margin for error. The EV/EBITDA of 18.01 is the friendlier lens, because it credits the ₹63 crore of net cash and looks at the business before the heavy depreciation charge. The P/E is the harsher lens, and it is the one that matters to a shareholder, because depreciation on laboratory equipment is a real recurring cost, not an accounting artefact.

Valuation framework

The scenario model starts with TTM EPS of ₹17.84. For each year it applies EPS_TTM × (1 + growth)^(year − 2026 + 112/365) × exit P/E, then rounds the result to the nearest ₹5. The 112/365 factor represents the fraction of the first forecast year remaining from 10 September to 31 December. Dividends are excluded.

Scenario	Annual EPS growth	Exit P/E	Business interpretation
Bear	8%	22×	Growth settles near the recent 10.7% and the multiple reverts toward a capital-intensive services rating
Base	13%	30×	Growth holds close to the five-year sales CAGR, margin is defended, rating drifts modestly lower
Bull	18%	40×	Regulated pharma and device testing scales, mix improves and the market keeps paying up for the accreditation moat

The growth rates are all set below the 29.96% five-year profit CAGR on purpose. A company that compounded profit at thirty per cent off a far smaller base will find that harder from about ₹80 crore, and the most recent year already shows the deceleration. The multiples run from clearly below the current rating to modestly above it, so no scenario assumes both perfect execution and permanent multiple expansion. The full method behind these inputs is set out in the guide on how to value a stock. These are scenarios, not probability-weighted forecasts.

Vimta Labs share price target 2026 to 2030

The grid is generated only from the three disclosed inputs: trailing EPS, an annual growth rate and an exit multiple. It models nothing else. It does not account for a share issue, an acquisition, a new laboratory coming on stream, a large environmental or clinical contract, an exceptional item, a change in dividend policy or a regulatory action against an accreditation. It also assumes earnings compound smoothly, which laboratory revenue does not. Rebuild the inputs after each annual result rather than carrying these forward.

Risks that can break the thesis

The first risk is the one already visible in the numbers: a starting multiple set by a thirty per cent history against a current trend near ten. Multiple compression can produce a poor shareholder return even while profit rises.

The second is accreditation. Every high-margin service line depends on a certificate that an inspector can suspend. A single adverse regulatory finding at a facility would remove revenue and reputation at the same time, and the recovery is measured in years, not quarters. This is the specific risk that distinguishes a laboratory from an ordinary services business.

The third is capital intensity. The twelve-point gap between the 34.66% operating margin and the 22.7% margin after depreciation is a standing reminder that this business must keep buying instruments to stay accredited. Growth that requires proportional capital spending compounds more slowly than the headline margin suggests.

Beyond those: environmental and infrastructure testing follows a capex cycle that can turn; clinical research volumes depend on pharmaceutical development budgets that can be cut; and at a ₹2,810 crore market capitalisation, position sizing and exit liquidity are practical constraints, not theoretical ones.

What would change the picture

The case strengthens if revenue growth returns above the mid-teens with the operating margin intact, if ROCE holds at or above the 25% mark while the asset base expands, and if the mix shifts toward regulated pharmaceutical, biologics and medical device work rather than commodity food and water panels. Net cash being deployed into new capacity that earns the existing return would also support the rating.

It weakens if margin falls while revenue grows, which would signal price competition in the volume lines; if receivables lengthen materially, which is common when environmental and government-linked work dominates; if ROCE drifts below the 23.87% five-year average as new capacity is added; or if a second and third year of roughly ten per cent growth confirm that the thirty per cent era has ended. Any regulatory action against a facility requires immediate reassessment regardless of the model.

Monitoring scorecard

Question	Constructive evidence	Warning sign
Are receivables converting to cash?	Debtor days flat or shorter while environmental and government-linked work grows	Operating cash generation lags reported profit two years running
Is capex turning into revenue?	New instruments and chambers bill work within a year of commissioning	The gross block grows faster than sales across successive years
Is export-facing work gaining share?	Analytical and clinical work billed against USFDA, EMA and other export-market filings takes a larger slice	Export-facing volumes flat while domestic repeat panels carry the growth
Is the revenue base widening?	Disclosed client and vertical concentration falls as capacity is added	One customer or one vertical starts to carry the order book
Is depreciation being outrun?	The gap between EBITDA and operating margin narrows	Depreciation grows faster than revenue
Is the accreditation record clean?	Inspections passed, no adverse findings	Any suspension, observation or facility action
Is the balance sheet still simple?	Net cash maintained, pledge stays nil	Debt added or promoter shares pledged

FAQ

What is the Vimta Labs share price target for 2026?

The 2026 line in the scenario grid is generated from trailing EPS of ₹17.84 compounded for the 112 days remaining in the calendar year, then multiplied by each scenario’s exit P/E. Because only about a third of a year of growth applies, the 2026 figures are driven almost entirely by the multiple, not by the growth rate. Read it as a range of outcomes, not a forecast.

What is the Vimta Labs share price target for 2030?

The 2030 line applies four years plus the same 112-day stub of compounding to the starting EPS at each scenario’s growth rate, then applies that scenario’s exit multiple. The spread across the three cases is wide by design, because compounding a growth assumption over more than four years magnifies any error in it. It is an illustration of how sensitive the outcome is to the assumptions, not a promised price.

What does Vimta Labs do?

It is a contract research and testing organisation founded in 1984 and based in Hyderabad. It runs preclinical, clinical and analytical research for biopharmaceutical and medical device companies, and separately provides food and beverage testing, water testing, environmental impact assessment and monitoring, and EMI/EMC testing for electronics manufacturers.

Who are the promoters of Vimta Labs?

The promoter group held 65.68% of the equity at the 10 September 2026 cut-off, with nil shares pledged. That is a high and clean promoter stake for a micro-cap. The identity of individual promoters and any changes to the holding are disclosed in the quarterly shareholding pattern filings on the company’s investor page.

Why has the Vimta Labs share price been falling?

The stock was about 23.76% below its 52-week high of ₹825.05 at the cut-off, having traded as low as ₹380.70 in the same window. The most obvious explanation in the captured data is the growth slowdown: revenue growth of 11.8% and earnings growth of 10.7% year on year against a five-year profit CAGR near 30%. When a multiple is set by the old growth rate and the new one arrives lower, the price adjusts before the earnings do.

Is Vimta Labs listed on both NSE and BSE?

The company’s own investor relations page shows both an NSE line under the symbol VIMTALABS and a BSE line under scrip code 524394. All price, market capitalisation and valuation figures in this article are taken against the NSE symbol. The exchange websites remain the authoritative record for the listing itself and for corporate action dates.

Related research

• Anthem Biosciences share price target
• Divi’s Laboratories share price target
• Kronox Lab Sciences share price target
• How to value a stock: the method behind every target here
• P/E ratio formula: meaning and calculation
• Return on equity: formula and interpretation

Sources and methodology

• Vimta Labs on Screener.in
• Vimta Labs quote and filings on NSE
• Vimta Labs company website
• Vimta Labs investor relations disclosures

Price, 52-week range, market capitalisation, trailing EPS, book value, revenue, EBITDA, debt, cash, share count and employee count were captured on 10 September 2026 from Yahoo Finance after the completed session. The ratio set covering operating margin, ROCE, the five-year average ROCE, ROE, PEG, EV/EBITDA, the five-year sales and profit CAGRs, promoter holding and pledge is Screener-derived and dated 5 August 2026; where the two dates disagree, as they do on market capitalisation and the 52-week high, both readings are shown with their dates. No Screener financial statement tables and no recent quarterly income statement were captured for this company, which is why the annual series above is sparse and why no quarterly section appears. Business descriptions come from the company record and the company website. Everything after that, including the reading of the PEG, the depreciation gap, the scenario growth rates and exit multiples, is analytical judgment and should be argued with rather than accepted.

---

This article is research and education, not personalised investment advice or a recommendation to transact. Gale is not a SEBI-registered investment adviser. The scenarios are illustrations, not guarantees. Verify current exchange filings, liquidity, corporate actions and suitability, and consult a registered adviser before acting.